Product Detail


Share to:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Cas No. 1190392-22-3, (6S)-4,6,7,8-tetrahydro-4-oxo-Pyrrolo[1,2-a]pyriMidine-6-carboxylic acid

  • 1190392-22-3

  • C8H8N2O3

  • 180.16

  • 1.61±0.1

  • 98% min (HPLC)

  • 392.2±44.0

  • Overactive Bladder

  • Vibegron

  • 12/1/2030 (Vibegron)

  • beta-3 adrenergic receptor

  • N

  • 2020

  • GMP



By selectively targeting the β3-adrenergic receptor, Vibegron exhibits superior efficacy and tolerability compared to traditional OAB medications. With its rapid onset and prolonged duration, Vibegron empowers patients and healthcare providers to manage OAB symptoms with a simplified and effective approach. By integrating Vibegron into your pharmaceutical portfolio, you can expand your impact on patients' quality of life and establish a new standard of care in OAB treatment.


The predominant components of Vibegron, the pyrrolidine imine part with three chiral centers (A), and the pyrrolopyrimidine part with one chiral center(B), are synthesized from specific compounds.

Final steps of Vibegron synthesis

The pyrrolidine imine part (A) is derived from the compound with CAS RN 1295539-30-8, or its Boc-protected alternative, CAS RN 1190391-85-5. Whereas, the pyrrolopyrimidine part (B) can take various acid forms of the current compound or its sodium salt equivalent, CAS RN 1421271-01-3, such as hydrochloride acid, tartaric acid, malic acid, mandelic acid, and maleic acid.

The selection of the sodium salt may require additional acid to extract the pyrrolopyrimidine moiety, potentially adding complexity to your manufacturing process. However, choosing the acid salt forms omits the need for additional acid during handling, thereby easing the route towards commercialization of Vibegron.


吕宏海, 郭万成, 房杰, 王国平 & 于振鹏. 一种维贝格龙中间体及其制备方法. (2023).


Berger, R. et al. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists. (2009).


Nagabukuro, H., Edmondson, S. D., Sinharoy, M. S., Denney, W. S. & Frenkl, T. L. Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent. (2011).


Xu, F. et al. Synthesis of Vibegron Enabled by a Ketoreductase Rationally Designed for High pH Dynamic Kinetic Reduction. Angew Chem Int Ed 57, 6863–6867 (2018).

Yasuda, N. et al. Process for making beta 3 agonists and intermediates. (2013).

US20090253705A1 - Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists